3D Medicines

Mission

We are dedicated to providing precision diagnosis  solutions to any patient, anytime, anywhere.  

Established in Shanghai in 2010, 3D Medicines (3DMed) is one of the first companies to provide oncology precision medical testing services in China. Over the years, the Company has grown into a successful Group consisting of 3DMed Diagnostics (Full company name: Etis Biotechnology (Shanghai) Co., Ltd.) .With the former already well-established as a market leader in automated and smart precision diagnostics in China.

The Group has received more than CNY 4 billion in investments from renowned venture capital firms, including more than CNY 20 billion for 3DMed Diagnostics. The Company has more than 1100 employees, including more than 300 R&D personnel, and has applied/owns nearly 200 patents. Having built a comprehensive R&D platform that integrates engineering, electrical, life science technologies, materials science, and artificial intelligence data analysis, the Company is able to realize fully automated R&D and manufacturing operations, as well as smart data processing, in the field of precision diagnosis

In addition, the Company uses industry-leading third-party medical test centers with dual CAP/CLIA accreditation to offer precision diagnostic services to a network in which core AAA hospitals account for more than 70%). The Company works with more than 800 hospitals, to provide them with products and services that cover the entire process of precision medicine from early disease diagnosis, companion diagnostics to dynamic monitoring. 

Guided by its “Patients First” motto, the Company stepped up and joined the fight against the pandemic immediately after the outbreak of the novel coronavirus in 2020. Due to its significant contributions, the Company, based in Minhang district was recognized as a “key organization in the fight against COVID19 pandemic (Shanghai)". At the same time, the Company has assisted in the global fight against the pandemic by developing related products and solutions such as novel coronavirus nucleic acid test kit, automated nucleic acid extraction kit, and mobile testing shelters. Its products and services are available in more than 60 countries and regions including Europe, U.S., Brazil, Australia, Middle East, Southeast Asia, and Africa.